WO2006087039A1

WO2006087039A1 - Broad spectrum anti viral herbal composition

Info

Publication number: WO2006087039A1
Application number: PCT/EP2005/050696
Authority: WO
Inventors: Antonia Rodriguez-Gonzalez
Original assignee: PROPHAREX SA
Current assignee: PROPHAREX SA
Priority date: 2005-02-17
Filing date: 2005-02-17
Publication date: 2006-08-24
Anticipated expiration: 2007-08-17

Abstract

The present invention relates to a safe broad spectrum anti viral herbal remedy with an outstanding efficiency against acute viral syndromes and infections. It can be administered topically, orally, rectally, vaginally, nasally, through aerosol inhalation or parenterally. The composition drastically reduces symptoms caused by nearly all known viruses at a rate far exceeding general accepted recovery times measured by means of General Accepted Medical Observation Methods. The composition also inhibits viral proliferation and/or activity in nearly all acute viral infections and prevents recurring outbreak of viral syndromes.

Description

BROAD SPECTRUM ANTI VIRAL HERBAL COMPOSITION

Technical Field

[1] The present invention relates to a safe broad spectrum anti viral herbal remedy with an outstanding efficiency against acute viral syndromes and infections. It can be administered topically, orally, rectally, vaginally, nasally, through aerosol inhalation or parentally. The composition drastically reduces symptoms caused by nearly all known viruses at a rate far exceeding general accepted recovery times measured by means of General Accepted Medical Observation Methods. The composition also inhibits viral proliferation and/or activity in nearly all acute viral infections and prevents recurring outbreak of viral syndromes.

Background Art

[2] The conventional approach to the control of virus-induced diseases is to develop effective vaccines, but this is not always possible. The objective of antiviral activity is to eradicate the virus while minimally impacting the host and to prevent further viral invasion. However, because of their method of replication, viruses present a greater therapeutic challenge than do bacteria.

[3] Viruses are comprised of a core genome of nucleic acid surrounded by a protein shell or capsid. Some viruses are further surrounded by a lipoprotein membrane or envelope. Viruses cannot replicate independently and, as such, are obligate intracellular parasites. The host's pathways of energy generation, protein synthesis, and DNA or RNA replication provide the virus with the means of viral replication. Viral replication occurs in five sequential steps: host cell penetration, disassembly, control of host protein and nucleic acid synthesis such that viral components are made, assembly of viral proteins, and release of the virus.

[4] Drugs that target viral processes must penetrate host cells; in doing so, they are likely to negatively impact normal pathways of the host. As such, antiviral drugs are characterized by a narrow therapeutic margin. Therapy is further complicated by viral latency, i.e. the ability of the virus to incorporate its genome in the host genome, with clinical infection becoming evident without re-exposure to the organism. In vitro susceptibility testing must depend on cell cultures, which are expensive. More importantly, in vitro inhibitory tests do not necessarily correlate with therapeutic efficacy of antiviral drugs. Part of the discrepancy between in vitro and in vivo testing occurs because some drugs require activation (metabolism) to be effective.

[5] Elucidation of viral biochemistry has been slow, contributing to slow pharmaceutical development. Only a few agents have been found to be reasonably safe and effective against a limited number of viral diseases. Most antiviral drugs interfere with viral nucleic acid synthesis or regulation. Such drugs generally are nucleic acid analogues that interfere with RNA and DNA production. Other mechanisms of action include interference with viral cell binding or interruption of virus uncoating. Some viruses contain unique metabolic pathways that serve as a target of drug therapy. Drugs that simply inhibit single steps in the viral replication cycle are virustatic and will only temporarily halt viral replication. Thus, optimal activity of some drugs depends on an adequate host immune response.

[6] Some antiviral medication which contain for example Echinacea and Taxus brevifolia may enhance the immune system of the host. However it has little effect when the viral infection is acute.

[7] Other medication containing for example Ribavirin and Interferon can reduce the amount of secreted enveloped viral RNA, but the therapeutic applications are limited to some viral infections such as Hepatitis C and studies have shown subjects suffering substantial negative side effects.

[8] Some inventors such as FR2706307 and FR2563109 have compiled several herbal substances and contribute the result as an effective anti viral synergy even claiming to cure AIDS. However, after over ten years no such effects have been proven. The problem these researchers face is that the substances they use might have some anti viral properties and they think that by piling them up they will result in an all powerful anti viral medicine. Tests have proven the contrary.

[9] It is not because you stack a lot of small bricks you build a solid wall. When the bricks are relatively small you need a type of cement to bind them together to build a solid wall. The definition of synergy is that the sum of 2 or more agents (e.g. herbs, synthetic compositions etc.) working together produces an effect greater than the combined effect of the same agents used separately. The key lays in the word SUM.

[10] What the majority of researchers try do is identify a synergy =

(agentl;AND;agent2;AND;agent3). The formula, however, should read : synergy =(agentl;SUMl;agent2;SUM2;agent3) whereas SUMl is a specific molecular or chemical structure binding agentl with agent2 and SUM2 a specific molecular or chemical structure binding agent2 with agent3.

[11] The problem lies in identifying the specific binding agent, which in the majority of the cases is a complex herbal substance itself. Even when working with less than 1000 herbal substances, we have to deal with billions of possible combinations. In relation to man-made chemical structure working with only a few molecules, herbal sunbstances consist of hundreds+ of molecules. Further it should be taken into consideration that tests have to be performed in vivo because as already mentioned, most of the herbal drugs require activation (metabolism) to be effective.

[12] To overcome this burden, inventors of said described anti viral composition had to first develop specific hard and software to be able to reduce the possible combinations from billions to a few thousand. At that time only, in vivo testing was economical feasible. Fortunately after less than a few hunderd in vivo tests they arrived to said composition, which is basically a virtual super-molecule. Further at the time of this application over 600 in vivo case studies have confirmed the potential of this break through medication. Presently hundreds of case studies are being performed periodically with very positive results.

[13] The patent is filed through a problem/solution/effects approach with brief description of symptoms and virus identification. It is understood that in-depth information on all mentioned viruses can be found in standard medical literature.

[14] It is also understood that in case of secondary infections (bacteria, mycoplasm etc.) the subject should be treated with other specific infection related medication. Disclosure of Invention

Medical Problems

[15] Medical Problem 01: Subjects having following symptoms : Blisters anywhere on the body, but especially near the mouth or genital areas. Some subjects experienced prodromal symptoms: tingling, pain, burning, or itching in the area a few days before the blisters appear.

[16] Diagnose Medical Problem 01: Herpes simplex virus infection (common names: herpes, cold sores) a common, contagious, incurable, and in some cases sexually transmitted disease caused by a double-stranded DNA virus

[17] Medical Problem 02: Subjects manifesting following symptoms : lassitude, malaise and fever occur and the hallmark of varicella, an itchy, blister-like rash appears. Starting on the scalp and face, the rash gradually spreads to the trunk and extremities as the first vesicles begin to dry out

[18] Diagnose Medical Problem 02: varicella-zoster virus (VZV), also known as

Human herpesvirus 3 (HHV-3), one of the eight herpesviruses known to affect humans (and other vertebrates). It causes chickenpox as a primary infection and rarely VZV encephalitis. It can remain dormant in the host and later reactivates to induce shingles (herpes zoster, zoster multiplex, myelitis, herpes ophthalmicus, or zoster sine herpete) and post-herpetic neuralgia.

[19] Medical Problem 03: Subjects manifesting following symptoms: immunocompromised patients, including organ transplant recipients, patients undergoing haemodialysis, patients with cancer, patients receiving immunosuppressive drugs, and HIV-infected patients, manifesting Pneumonia, retinitis, and gastrointestinal disease.

[20] Diagnose Medical Problem 03: Cytomegalovirus ( CMV), a genus of Herpes viruses; in humans the species is known as Human herpesvirus 5 (HHV-5). It belongs to the Betaherpesvirinae subfamily of Herpesviridae.

[21] Medical Problem 04: Children between 6 months and 3 years of age, experiencing sudden high fever of 39-40 degrees Celsius. In some cases, there are febrile convulsions (also known as febrile seizures or fever fits) - due to the suddenness of the rise in body temperature. After a few days the fever subsides and just as the child appears to be recovering, a red rash appears. This usually begins on the trunk, spreading to the limbs but usually not affecting the face. It disappears again in a matter of hours to a day or so.

[22] Diagnose Medical Problem 04: Exanthem subitum (meaning sudden rash), also referred to asroseola infantum, sixth disease.

[23] Medical Problem 05: Subjects manifesting following symptoms: Visual warts in the genital areas. Invisible warts; detected in the genital tissue by applying vinegar (acetic acid) to areas of suspected infection and a colposcopy is performed. In other cases, they eventually develop a fleshy, small raised growth that looks like cauliflower developed.

[24] Diagnose Medical Problem 05: Human papillomavirus (HPV) a virus which affects humans. Some of its effects are classed as sexually transmitted disease (STD). Although treatments can get rid of the warts, none gets rid of the virus. Because the virus is still present in your body, warts often come back after treatment

[25] Medical Problem 06: Subjects manifesting following symptoms: flesh-coloured, pea-sized or smaller bumps (called lesions) with a dimpled centre that may itch and become irritated, tender or painful. In young children the body, arms, and legs are affected. In adults the genitals, lower abdomen, buttocks and inner thighs are affected. In rare cases contagiosum infection. In about 10% of the cases, eczema develops.

[26] Diagnose Medical Problem 06: Molluscum contagiosum (also called water wart) skin disease caused by the molluscum contagiosum virus (or MCV), a DNA poxvirus. Symptoms disappear within 6 months to 2 years. Medical treatments for this condition include cryosurgery, where liquid nitrogen is used to freeze and destroy the lesion, as well as scraping them off with a curette. Side-effects from these treatments include permanent discoloration and scarring.

[27] Medical Problem 07 : Subjects manifesting following symptoms : Vomiting, watery diarrhoea, and low-grade fever

[28] Diagnose Medical Problem 07 : Rotavirus , causing acute gastroenteritis.

Infantile diarrhoea, winter diarrhoea, acute nonbacterial infectious gastroenteritis, and acute viral gastroenteritis are names applied to the infection caused by the most common and widespread group A rotavirus. The virus is more commonly known as the Stomach Flu, although it shares no resemblance to an actual flu.

[29] Medical Problem 08 : Subjects manifesting following symptoms : Cough that produces mucus, Shortness of breath, worsened by activity, Wheezing, Fatigue, Low- grade fever, Chest discomfort, malaise

[30] Diagnose Medical Problem 08 : Infectious Bronchitis virus causing an inflammation of the bronchi of the lungs, which causes the cilia of the bronchial epithelial cells to stop functioning. There is no specific cure for the disease

[31] Medical Problem 09 : Subjects manifesting following symptoms : fatigue, loss of appetite, nausea and vomiting, fever, weakness, mild abdominal pain.

[32] Diagnose Medical Problem 09 : Hepatitis C , (HCV) a form of hepatitis (liver inflammation) causing long term damage to the liver, including cirrhosis and hepatocellular carcinoma

[33] Medical Problem 10 : Subjects manifesting following symptoms : acute severe inflammation of the liver

[34] Diagnose Medical Problem 10 : Hepatitis E a contagious virus that causes acute

(non-chronic) hepatitis. It is most common in adults between the ages of 15 and 40. During the duration of the infection (usually several weeks), the disease severely impairs a person's ability to work, care for family members, and obtain food. Hepatitis E occasionally develops into an acute liver disease, and is fatal in about 2% of all cases. Clinically, it is comparable to hepatitis A, but in pregnant women the course can be fulminant. Pregnant women generally suffer an elevated mortality rate from the disease

[35] Medical Problem 11 : Subjects manifesting following symptoms : fever, muscle aches, headache and backache. Other symptoms include a red tongue, flushed face, and reddening of the eyes

[36] Diagnose Medical Problem 11 : Yellow fever (also called black vomit or sometimes The American Plague) an acute viral disease

[37] Medical Problem 12 : Subjects manifesting following symptoms : swollen glands, fever, rash, flaking, dry skin, inflammation of the eyes, nasal congestion, joint pain and swelling, pain in the testicles

[38] Diagnose Medical Problem 12 : Rubella (also known as epidemic roseola,

German measles or three-day measles) a disease caused by the Rubella virus and is know to have negative effects on the development of foetuses when the disease is contracted by pregnant women.

[39] Medical Problem 13 : Subjects manifesting following symptoms : fatigue, fever, vomiting, headache, pain in the neck and extremities

[40] Diagnose Medical Problem 13 : Poliomyelitis ('polio') a viral paralytic disease.

The causative agent is a virus called poliovirus (PV)

[41] Medical Problem 14 : Subjects manifesting following symptoms : jaundice

(showing up first as yellow eyes), dark urine, nausea, fever, tiredness, loss of appetite, stomach ache, vomiting [42] Diagnose Medical Problem 14 : Hepatitis A , a disease affecting the liver, and caused by the Hepatitis A virus (abbreviated HAV) [43] Medical Problem 15 : Subjects manifesting following symptoms : sneezing, sniffing, running/blocked nose (often these occur simultaneously, or one in each nostril), scratchy, sore, or phlegmy throat, coughing, headache, and a general feeling of unwellness; they last between 3 to 10 days, with residual coughing lasting up to 3 weeks. [44] Diagnose Medical Problem 15 : Common cold a mild viral infectious disease of the nose and throat, the upper respiratory system [45] Medical Problem 16 : Subjects manifesting following symptoms : fever for at least 3 days duration, and the three Cs - cough, coryza (runny nose) and conjunctivitis

(red eyes). The fever may reach up to 40 degrees Celsius. Koplik's spotsseen inside the mouth [46] Diagnose Medical Problem 16 : Measles , also known as rubeola, a common disease caused by a virus of the genus Morbillivirus [47] Medical Problem 17 : Subjects manifesting following symptoms : face pain, swelling of the parotid glands (neck swelling) (in 60%-70% of cases), fever, headache, sore throat, swelling of the temples or jaw (temporomandibular area), Additional symptoms in males that may be associated with this disease (in 20 to 30% of cases): testicular pain, testicular enlargement, scrotal swelling. [48] Diagnose Medical Problem 17 : Mumps virus or Epidemic parotitis a viral disease of humans with possible negative effects on male fertility. [49] Medical Problem 18 : Subjects manifesting following symptoms : fever, headache, tiredness (can be extreme), dry cough, sore throat, nasal congestion, sneezing, body aches [50] Diagnose Medical Problem 18 : Influenza (or as it is commonly known, the flu) a contagious disease caused by an RNA virus of the orthomyxoviridae family [51] Medical Problem 19 : Subjects manifesting following symptoms : initial symptoms are flu-like and may include: fever, myalgia, lethargy, gastrointestinal symptoms, cough, sore throat and other non-specific symptoms. The only symptom that is common to all patients appears to be a fever above 38 ⁰C (100.4 ⁰F). Shortness of breath may occur later [52] Diagnose Medical Problem 19 : Severe Acute Respiratory Syndrome (SARS) is an atypical form of pneumonia untill recently attributed to a mutant Coronavirus, however recent reports contradict this. Exact virus type not identified. [53] Medical Problem 20 : Subjects manifesting following symptoms : fever, sore throat, and swollen lymph glands. Sometimes, a swollen spleen or liver involvement may develop [54] Diagnose Medical Problem 20 : Epstein-Barr virus, frequently referred to as

EBV, is a member of the herpesvirus family and one of the most common human viruses [55] Medical Problem 21 : Subjects (birds) manifesting following symptoms :

Depression, drop in egg production, pale shelled eggs, low morality, nasal discharge, coughing and sneezing, head twisting and nervous symptoms. Humans having inlfuenza type symptoms. [56] Diagnose Medical Problem 21 : Newcastle Disease a highly contagious viral disease, which is known to infect all domestic and wild birds. Birds can die of the disease quite quickly after developing symptoms. Very seldomly transferred to humans. However, could lead to a virtual uncontrolable viral pandemic outbreak at the time of this application. [57] Medical Problem 22 : Subjects manifesting following symptoms : fever and painful blisters in the mouth, on the palms and fingers of the hand, or on the soles of the feet. Other diseases include acute haemorrhagic conjunctivitis , herpangina, and aseptic meningitis [58] Diagnose Medical Problem 22 : Coxsackie virus a cytolytic virus of the Picor- naviridae family, a enterovirus (a group containing the polioviruses, coxsackieviruses, and echoviruses). There are 61 non-polio enteroviruses that can cause disease in humans, of them 23 are Coxsackie A viruses, 6 are Coxsackie B viruses. Enterovirus " are the second most common viral infectious agents in humans (after the rhinoviruses) [59] Medical Problem 23 : Subjects manifesting following symptoms : Fever, fatigue, muscle or joint pain, loss of appetite, mild to severe nausea and vomiting, yellow eyes and skin ('jaundice'), bloated or swollen stomach [60] Diagnose Medical Problem 23 : Hepatitis B the most common serious liver infection in the world. It is caused by the hepatitis B virus that attacks the liver. The virus is transmitted through blood and infected bodily fluids. [61] Medical Problem 24 : Subjects manifesting following symptoms : Jaundice, fatigue, abdominal pain, loss of appetite, nausea, vomiting, joint pain, dark (tea colored) urine [62] Diagnose Medical Problem 24 : Hepatitis D a liver disease caused by the hepatitis D virus (HDV), a defective virus that needs the hepatitis B virus to exist.

Hepatitis D virus (HDV) is found in the blood of persons infected with the virus [63] Medical Problem 25 : Subjects manifesting following symptoms : headache, high fever, neck stiffness, stupor, disorientation, coma, tremors, convulsions, muscle weakness, and paralysis. [64] Diagnose Medical Problem 25 : West Nile encephalitis or meningitis or West Nile poliomyelitis WNV is established as a seasonal epidemic especially in North America that flares up in the summer and continues into the fall.

Medical Solution

[65] A composition of 100% pure natural synergetic substances from various plants having anti- viral properties.

[66] Said composition contains at least following groups of molecules: Monoterpenes,

Sesquiterpenes, Monoterpene alcohols, Sesquiterpene alcohols, Monoterpene aldehydes, Monoterpene ketones, Monoterpene esters, Sesquiterpene ketones, Monoterpene esters, Terpenoid oxides, Phenols, Phenylpropanoid ether, Non-terpenic esters, Coumarins

[67] Detailled common Composition : dihydrocarveol, myrtenol, δ-3-carene, di- hyrocarvyl acetate, ethyl hexanoate, α -elemene, α -copaene, 1.4-cineole, borneol, cadinol, geranyl acetate, vetiveryl acetate, α- and β-vetivone, longicylene, trans-linalol oxide, myrcene, 1.8-cineole, camphor, lavandulyl acetate, tricyclovetivene, menthol,terpinolene, myrtenal, α-humulene, viridiflorene, cis-carvyl acetate, farnesene, camphene, vetivene, myrtenyl acetate, isoleucine methyl ester, isoborneol, 2-nonanyl acetate, trans-anethole, linalyl acetate, calamine, elemol, 2-hydroxypiperitone (diosphenol), β-caryophyllene, farnesol, thuyan-4-ol, trans-nerolidol, α-muurolene, byakangelicine, α- and δ-cadinene, 2-heptanyl acetate, α- and γ-terpinene, isopimpinellin, eugenol, carvone, neohydrocarveol, tricyclene, hotrienol, spathulenol, citral, citronellal, viridiflorol, geranial, sesilin, aurapten, p-cymene, α-phellandrene, limonene, terpinen-4-ol, chavicol (4-allyl phenol), aromadendrene, neral, bornyl acetate, bergamottin, geranyl 2-methyl proprionate, longiborneol, linalol, 5-geranoxy-7-methoxycoumarin, menthone, pulegone, globulol, α- and β-pinene.

[68] Said common composition is derived through extraction of plants preferably from the following plant families, indicated by the part of the plant used, its specific chemical composition and Major component:.

[69] 1. Family: Lamiaceae. Used part: Leaf. Chemical composition: monoterpenes, sesquiterpenes, monoterpene alcohols, sesquiterpene alcohols, monoterpene esters, terpenoid oxides, monoterpene ketones. Major component: (-)-carvone

[70] 2. Family: Lamiaceae. Used parts: flowering tops. Chemical composition: monoterpenes, sesquiterpenes, sesquiterpene alcohols, phenols, monoterpene ketones, Major component: isopinocamphone

[71] 3. Family: Asteraceae. Used parts: plant. Chemical composition: coumarins, phenols. Major component: chavicol M.E.

[72] 4. Family: Labiatae. Used parts: whole plant + leaf. Chemical composition: monoterpene alcohols, monoterpene aldehydes. Major component: geraniol

[73] 5. Family: Rutaceae. Used parts: leaf. Chemical composition: keto-alcohols, monoterpene ketones, . Major component: (-)-isomenthone [74] 6. Family: Myrtaceae. Used parts: leaf. Chemical composition: monoterpenes, sesquiterpenes, sesquiterpene alcohols, monoterpene alcohols, terpenoid oxides. Major component: terpinen-4-ol [75] 7. Family: Myrtaceae. Used parts: leaf. Chemical composition: sesquiterpenes, monoterpene alcohols, terpenoid oxides. Major component: (+)-trans-nerolidol [76] 8. Family: Rutaceae. Used parts: peel. Chemical composition: monoterpenes, monoterpene esters, monoterpenes alcohols, coumarins and furocoumarins. Major component: linalyl acetate [77] 9. Family: Poaceae. Used parts: plant. Chemical composition: monoterpene alcohol, sesquiterpene alcohols, monoterpene aldehydes, sesquiterpene aldehydes. Major component: citral [78] 10. Family: Myrtaceae. Used parts: leaf. Chemical composition: monoterpenes, sesquiteipenes, monoterpene alcohol, monoterpene esters, monoterpene oxides, monoterpene aldehydes, lactones. Major component: 1.8-cineol [79] 11. Family: Caprifoliaceae. Used parts: flowers. Chemical composition: hotrienol, isoleucin methyl ester [80] 12. Family: Abietaceae. Used parts: leafs. Chemical composition: monoterpenes, sesquiterpene alcohols, monoterpene alcohols, sesquiterpenes. Major component: terpineol [81] 13. Family: Abietaceae. Used parts: Needles. Chemical composition: monoterpenes, sesquiteipenes, monoterpene alcohols, monoterpene esters, sesquiterpene alcohols.

Major component: (-)-bornyl acetate [82] 14. Family: Poaceae. Used parts: roots. Chemical composition: sesquiterpenes, sesquiterpene alcohols, sesquiterpene esters, sesquiterpene ketones. Major component: equal parts of all groups. [83] 15. Family: Lauraceae. Used parts: Bark. Chemical composition: monoterpene esters, monoterpenes oxides, monoterpene alcohols, sesquiterpenes, monoterpenes.

Major component: (-)-alpha-terpineol 1.8-cineol [84] 16. Family: Lauraceae. Used parts: Bark. Chemical composition: phenols, sesquiterpenes, sesquiterpene alcohols. Major component: chavicol M.E. [85] 17. Family: Myrtaceae Used parts: leaf. Chemical composition: aliphatic monoterpene aldehydes, terpenoid oxides, sesquiterpene alcohols, monoterpene alcohols, sesquiterpenes, monoterpenes. Major component: 1.8-cineol [86] 18. Family: Myrtaceae Used parts: bud. Chemical composition: terpenoid oxides, phenol ethers, sesquiterpenes. Major component: eugenol [87] 19. Family: Poaceae Used parts: plant. Chemical composition: monoterpene , monoterpenes aldehydes. Major component: geranial [88] The percentage of the substances derived form each plant my vary form 0.01 % to

75 % per plant in relation to the whole composition.

[89] The base is an essential oil composition

[90] Improvement of symptoms has been observed with as little as 0.025 ml and less per

10 kg body weight administered daily. Overall best results are reached with the administration of 0.05 ml per 10 kg body-weight, not including excess fat.

[91] Modes of administration are: oral, topical, rectal, vaginal, nasally, inhalation preferably by means of aerosol, parenterally, in rare cases intravenously.

Advantageous Effects

[92] Medical Problem 01: De-activation of Herpes simplex virus causes all symptoms to disappear within 12 and 72 hours. When herbal composition is administered at the onset of the firstsymptoms, rapid disappearance of prodromal symptoms without appearance of blisters.

[93] When administered when herpes is acute with typical symptoms, disappearance of blisters within a 12 to 72 hours and stopping the formation of new ones.

[94] When administered just before an expected outbreak, normally just before a stressful situationlike menstruation, symptoms do not appear at all. At the onset of the next expected outbreak no more symptoms appeared, confirming elimination or deactivation of the virus.

[95] Medical Problem 02 : De-activation of Varicella-zoster virus causes all symptoms to disappear within 12 to 72 hours.

[96] Medical Problem 03 : De-activation of Cytomegalo virus (CMV) causes all symptoms to disappear within 12 hours to 7 days.

[97] Medical Problem 04 : De-activation of Exanthem subitum virus causes all symptoms to disappear within 12 to 72 hours. More specific: disappearance of fever within hours after taking administration and disappearance of rash in the following period.

[98] Medical Problem 05 : De-activation of Human papillomavirus (HPV) causes all symptoms to disappear within 12 to 7 days. More specific: after early administration no new formation of papillomvirus relatedwartsafterwards rapid regression of warts. After late administration slow regression of warts without little or no need for surgical removal.

[99] Medical Problem 06 : De-activation of Molluscum contagiosum virus causes all symptoms to diminish drastically within 12 to 72 hours, on average complete recovery within 1 week.

[100] Medical Problem 07 : De-activation of Rotavirus virus causes all symptoms to disappear within 12 to 72 hours. More specific: abrupt stoppage of diarrhoea within 3 to 36 hours. [101] Medical Problem 08 : De-activation of Infectious Bronchitis virus causes all symptoms to disappear within 12 to 72 hours. More specific: fast recovery of healthy bronchial passages within 48 hours. [102] Medical Problem 09 : De-activation of Hepatitis C virus causes all symptoms to disappear within 12 to 72 hours. More specific : Inactivation of virus immediately stops viral damage to liver cells preventingeventual cancer and cirrhosis, within 24 hours fever goes down, within days the patient feels better, stronger, regains his appetite. No more abdominal pain. [103] Medical Problem 10 : De-activation of Hepatitis E virus causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within 1 week. [104] Medical Problem 11 : De-activation of Yellow Fever virus causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within 1 week. [105] Medical Problem 12 : De-activation of Rubella virus causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within 2-3 days.

Limitation of negative effects on feotus of pregnant subject when composition administered on the onset of the disease. [106] Medical Problem 13 : De-activation of Polio virus causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within 1 week [107] Medical Problem 14 : De-activation of Hepatitis A virus causes all symptoms to diminish drastically within 12 to 72 hours, liver function recovery depend on the damage already done by the virus. No more further damage to liver. [108] Medical Problem 15 : De-activation of Common cold virus causes all symptoms to diminish drastically within 12 to 48 hours, on average complete cure within 2 days or less. When administered at the onset of the cold, immediate ceasing of symptoms and cure. [109] Medical Problem 16 : De-activation of Morbillivirus causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within 2-3 days. [110] Medical Problem 17 : De-activation of Mumps virus causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within 2-3 days.

Limitation possible infertility when administered at the onset of the disease. [111] Medical Problem 18 : De-activation of Influenza virus causes all symptoms to diminish drastically within 12 to 48 hours, on average complete cure within 2 days or less. When administered at the onset of the disease, immediate ceasing of symptoms. [112] Medical Problem 19 : De-activation of virus causing Severe Acute Respiratory

Syndrome (SARS) causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within 2-3 days. [113] Medical Problem 20 : De-activation of Epstein-Barr virus causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within one week.

[114] Medical Problem 21 : De-activation of virus causing Newcastle Disease causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within 2-3 days. Depending on the time of administration, in general, fowl respond slighty faster to said compostion than humans.

[115] Medical Problem 22 : De-activation of Coxsackie virus causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within 2-3 days

[116] Medical Problem 23 : De-activation of Hepatitis B causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within one week.

[117] Medical Problem 24 : De-activation of Hepatitis D causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within one week.

[118] Medical Problem 25 : De-activation of West Nile virus causes all symptoms to diminish drastically within 12 to 72 hours, on average complete cure within 2-3 days

Best Mode

[119] The best mode administering the composition is one drop or + 0.05ml per 10 kg body weight (not including excess body fat), three times daily orally. Orally mixing with fruit juice or yoghurt, topically mixing with macadamia-type oil for fast topical absorption and petroleum jelly for slow topical absorption. For administering to animals composition can be mixed with the feed. Aerosol inhalation according to standard aerosol dispersions methods. Rectal or vaginal insertion of suppository with indicated dose according to standard suppository administration methods. Administer at least one day after all symptoms completely disappeared, when administered during or just before the initial outbreak of the symptoms.

Claims

Claims[1] A method of treating a viral infection comprising administering to a patient in need thereof a therapeutically effective amount of a composition of 100% pure natural synergetic substances from various plants having anti- viral properties Said composition contains at least the following groups of molecules: Monoterpenes, Sesquiterpenes, Monoterpene alcohols, Sesquiterpene alcohols, Monoterpene aldehydes, Monoterpene ketones, Monoterpene esters, Sesquiterpene ketones, Monoterpene esters, Terpenoid oxides, Phenols, Phenyl- propanoid ether, Non-terpenic esters, CoumarinsThe composition contains at least 60 of following substances: dihydrocarveol, myrtenol, δ-3-carene, dihyrocarvyl acetate, ethyl hexanoate, α -elemene, α - copaene, 1.4-cineole, borneol, cadinol, geranyl acetate, vetiveryl acetate, α- and β-vetivone, longicylene, trans-linalol oxide, myrcene, 1.8-cineole, camphor, lavandulyl acetate, tricyclovetivene, menthol,terpinolene, myrtenal, α-humulene, viridiflorene, cis-carvyl acetate, farnesene, camphene, vetivene, myrtenyl acetate, isoleucin, methyl ester, isoborneol, 2-nonanyl acetate, trans-anethole, linalyl acetate, calamine, elemol, 2-hydroxypiperitone (diosphenol), β-caryophyllene, farnesol, thuyan-4-ol, trans-nerolidol, α-muurolene, byakangelicine, α- and δ- cadinene, 2-heptanyl acetate, α- and γ-terpinene, isopimpinellin, eugenol, carvone, neohydrocarveol, tricyclene, hotrienol, spathulenol, citral, citronellal, viridiflorol, geranial, sesilin, aurapten, p-cymene, α-phellandrene, limonene, terpinen-4-ol, chavicol (4-allyl phenol), aromadendrene ,neral, bomyl acetate, bergamottin, geranyl 2-methyl proprionate, longiborneol, linalol, 5-geranoxy-7-methoxycoumarin, menthone, pulegone, globulol, α- and β-pinene. Said composition is derived through extraction of preferably the following plant families :

1. Family: Lamiaceae. Used part: Leaf. Chemical composition: monoterpenes, sesquiterpenes, monoterpene alcohols, sesquiterpene alcohols, monoterpene esters, terpenoid oxides, monoterpene ketones. Major component: (-)-carvone

2. Family: Lamiaceae. Used parts: flowering tops. Chemical composition: monoterpenes, sesquiterpenes, sesquiterpene alcohols, phenols, monoterpene ketones, Major component: isopinocamphone

3. Family: Asteraceae. Used parts: plant. Chemical composition: coumarins, phenols. Major component: chavicol M.E.

4. Family: Labiatae. Used parts: whole plant + leaf. Chemical composition: monoterpene alcohols, monoterpene aldehydes. Major component: geraniol

5. Family: Rutaceae. Used parts: leaf. Chemical composition: keto-alcohols, monoterpene ketones, . Major component: (-)-isomenthone

6. Family: Myrtaceae. Used parts: leaf. Chemical composition: monoterpenes, sesquiterpenes, sesquiterpene alcohols, monoterpene alcohols, terpenoid oxides. Major component: terpinen-4-ol

7. Family: Myrtaceae. Used parts: leaf. Chemical composition: sesquiterpenes, monoterpene alcohols, terpenoid oxides. Major component: (+)-trans-nerolidol

8. Family: Rutaceae. Used parts: peel. Chemical composition: monoterpenes, monoterpene esters, monoterpenes alcohols, coumarins and furocoumarins. Majo r component: linalyl acetate

9. Family: Poaceae. Used parts: plant. Chemical composition: monoterpene alcohol, sesquiterpene alcohols, monoterpene aldehydes, sesquiterpene aldehydes. Major component: citral

10. Family: Myrtaceae. Used parts: leaf. Chemical composition: monoterpenes, sesquiterpenes, monoterpene alcohol, monoterpene esters, monoterpene oxides, monoterpene aldehydes, lactones. Major component: 1.8-cineol

11. Family: Caprifoliaceae. Used parts: flowers. Chemical composition: hotrienol, isoleucin methyl ester

12. Family: Abietaceae. Used parts: leafs. Chemical composition: monoterpenes, sesquiterpene alcohols, monoterpene alcohols, sesquiterpenes. Major component: terpineol

13. Family: Abietaceae. Used parts: Needles. Chemical composition: monoteipenes, sesquiterpenes, monoterpene alcohols, monoterpene esters, sesquiterpene alcohols. Major component: (-)-bornyl acetate

14. Family: Poaceae. Used parts: roots. Chemical composition: sesquiterpenes, sesquiterpene alcohols, sesquiterpene esters, sesquiterpene ketones. Major component: equal parts of all groups.

15. Family: Lauraceae. Used parts: Bark. Chemical composition: monoterpene esters, monoterpenes oxides, monoterpene alcohols, sesquiterpenes, monoterpenes. Major component: (-)-alpha-terpineol 1.8-cineol

16. Family: Lauraceae. Used parts: Bark. Chemical composition: phenols, sesquiterpenes, sesquiterpene alcohols. Major component: chavicol M.E.

17. Family: Myrtaceae Used parts: leaf. Chemical composition: aliphatic monoterpene aldehydes, terpenoid oxides, sesquiterpene alcohols, monoterpene alcohols, sesquiterpenes, monoterpenes. Major component: 1.8-cineol

18. Family: Myrtaceae Used parts: bud. Chemical composition: terpenoid oxides, phenol ethers, sesquiterpenes. Major component: eugenol

19. Family: Poaceae Used parts: plant. Chemical composition: monoterpenals, monoterpenes. The ratio of the components derived from each individual plant fall between 0.001 % and 75 % of the complete composition.

[2] A method according to claim 1 wherein said method comprises administering to a patient in need thereof from 0.001ml per 10 kg body weight to 10 ml per 10 kg body weight, not including excess body fat, at least one time.

[3] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Herpes simplex virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[4] A method according to claim 1 wherein said method permanently eliminates the

Herpes simplex virus in- vivo and prevents recurring outbreak of the symptoms.

[5] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Varicella-zoster virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[6] A method according to claim 1 wherein said method permanently eliminates the

Varicella-zoster in- vivo and prevents recurring outbreak of the symptoms

[7] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Cytomegalo virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[8] A method according to claim 1 wherein said method permanently eliminates the

Cytomegalo virus in- vivo and prevents recurring outbreak of the symptoms.

[9] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Exanthem subitum virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[10] A method according to claim 1 wherein said method permanently eliminates the

Exanthem subitum virus in- vivo and prevents recurring outbreak of the symptoms

[11] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Human papillomavirus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[12] A method according to claim 1 wherein said method permanently eliminates the

Human papillomavirus in- vivo and prevents recurring outbreak of the symptoms

[13] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Molluscum contagiosum at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[14] A method according to claim 1 wherein said method permanently eliminates the

Molluscum contagiosum in- vivo and prevents recurring outbreak of the symptoms.

[15] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Rotavirus virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[16] A method according to claim 1 wherein said method permanently eliminates the

Rotavirus virus in- vivo and prevents recurring outbreak of the symptoms.

[17] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Infectious Bronchitis virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[18] A method according to claim 1 wherein said method permanently eliminates the

Infectious Bronchitis virus in- vivo and prevents recurring outbreak of the symptoms

[19] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Hepatitis C virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[20] A method according to claim 1 wherein said method permanently eliminates the

Hepatitis C virus in- vivo and prevents recurring outbreak of the symptoms

[21] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Hepatitis E virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[22] A method according to claim 1 wherein said method permanently eliminates the

Hepatitis E virus in- vivo and prevents recurring outbreak of the symptoms

[23] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Yellow Fever virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[24] A method according to claim 1 wherein said method permanently eliminates the

Yellow Fever virus in- vivo and prevents recurring outbreak of the symptoms

[25] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Rubella virus at a rate far exceeding general accepted r ecovery times measured by means of General accepted medical observation methods.

[26] A method according to claim 1 wherein said method permanently eliminates the

Rubella virus in- vivo and prevents recurring outbreak of the symptoms

[27] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Polio virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[28] A method according to claim 1 wherein said method permanently eliminates the

Polio virus in- vivo and prevents recurring outbreak of the symptoms

[29] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Hepatitis A virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[30] A method according to claim 1 wherein said method permanently eliminates the

Hepatitis A virus in- vivo and prevents recurring outbreak of the symptoms

[31] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Common cold virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[32] A method according to claim 1 wherein said method permanently eliminates the

Common cold virus in- vivo and prevents recurring outbreak of the symptoms

[33] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Morbillivirus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[34] A method according to claim 1 wherein said method permanently eliminates the

Morbillivirus in- vivo and prevents recurring outbreak of the symptoms

[35] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Mumps virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[36] A method according to claim 1 wherein said method permanently eliminates the

Mumps virus in- vivo and prevents recurring outbreak of the symptoms

[37] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Influenza virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[38] A method according to claim 1 wherein said method permanently eliminates the

Influenza virus in- vivo and prevents recurring outbreak of the symptoms

[39] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Severe Acute Respiratory Syndrome (SARS) virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[40] A method according to claim 1 wherein said method permanently eliminates the

Severe Acute Respiratory Syndrome (SARS) virus in- vivo and prevents recurring outbreak of the symptoms

[41] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Epstein-Barr virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[42] A method according to claim 1 wherein said method permanently eliminates the

Epstein-Barr virus in- vivo and prevents recurring outbreak of the symptoms

[43] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Newcastle Disease at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[44] A method according to claim 1 wherein said method permanently eliminates the

Newcastle Disease in- vivo and prevents recurring outbreak of the symptoms

[45] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Coxsackie virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[46] A method according to claim 1 wherein said method permanently eliminates the

Coxsackie virus in- vivo and prevents recurring outbreak of the symptoms

[47] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Hepatitis B virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[48] A method according to claim 1 wherein said method permanently eliminates the

Hepatitis B virus in- vivo and prevents recurring outbreak of the symptoms

[49] A method according to claim 1 wherein said method drastically reduces symptoms caused by the Hepatitis D virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods. [50] A method according to claim 1 wherein said method permanently eliminates the

Hepatitis D virus in- vivo and prevents recurring outbreak of the symptoms

[51] A method according to claim 1 wherein said method drastically reduces symptoms caused by the West Nile virus at a rate far exceeding general accepted recovery times measured by means of General accepted medical observation methods.

[52] A method according to claim 1 wherein said method permanently eliminates the

West Nile virus in- vivo and prevents recurring outbreak of the symptoms